<DOC>
	<DOC>NCT02376608</DOC>
	<brief_summary>The study will evaluate the relative bioavailability of Pronovum PRF-037 and Pronovum PRF-041 with PronovaPure 150:150 EE EU and Eskimo-3 (500 mg omega-3 acid triglyceride containing 80 mg EPA and 50 mg DHA per gram oil) in healthy subjects.</brief_summary>
	<brief_title>Bioavailability of Omega-3 Food Supplement in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>males or females any ethnic origin BMI 18.5 30.0 kg/m2 generally in good health signed informed consent males or females not willing to use appropriate contraception prescribed systemic or topical medication within 14 days and slow release medication considered to be active within 14 days. omega3 fatty acids or fish oil within 2 weeks of dosing. any nonprescribed systemic or topical medication including herbal remedies and vitamin/mineral supplements within 7 days any medication incl. St.John's Worth known to chronically alter drug absorption/elimination within 30 days Subjects still present in clinical study or in the past 3 months recent blood donation drug allergy or significant allergic disease allergic or hypersensitivity to omega3 acids, fish, soya, oleic acid, sesame oil or other constituents in pharma preparation high consumption of alcohol high consumption of tobacco hepatitis or HIV vegetarians earlier participated in or withdrawn from the study not willing to follow dietary restrictions frequent occurence of migraine attacks subjects that should not participate according to investigator</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>